87 related articles for article (PubMed ID: 8877734)
1. Phase I/IB study of polyadenylic-polyuridylic acid in patients with advanced malignancies: clinical and biologic effects.
Witt PL; Zahir S; Ritch PS; McAuliffe TM; Ewel CH; Borden EC
J Interferon Cytokine Res; 1996 Aug; 16(8):631-5. PubMed ID: 8877734
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.
Witt PL; Ritch PS; Reding D; McAuliffe TL; Westrick L; Grossberg SE; Borden EC
Cancer Res; 1993 Nov; 53(21):5176-80. PubMed ID: 8221654
[TBL] [Abstract][Full Text] [Related]
3. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
[TBL] [Abstract][Full Text] [Related]
5. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
[TBL] [Abstract][Full Text] [Related]
6. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly.
Schiller JH; Storer BE; Witt PL; Alberti D; Tombes MB; Arzoomanian R; Proctor RA; McCarthy D; Brown RR; Voss SD
Cancer Res; 1991 Mar; 51(6):1651-8. PubMed ID: 1998956
[TBL] [Abstract][Full Text] [Related]
7. 2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals.
Witt PL; Spear GT; Lindstrom MJ; Kessler HA; Borden EC; Phair J; Landay AL
AIDS; 1991 Mar; 5(3):289-93. PubMed ID: 2059368
[TBL] [Abstract][Full Text] [Related]
8. [Changes in serum levels of beta 2-microglobulin, neopterin and 2',5'-oligoadenylate synthase activity during clearance of hepatitis B virus with or without acute phase in transaminases].
Carreño García V; Hernández-Guío C; Bartolomé Nebreda J; Quiroga Estévez JA
Rev Esp Enferm Dig; 1993 Mar; 83(3):169-75. PubMed ID: 7683894
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of natural killer cell activity and 2-5A synthetase in operable breast cancer patients treated with polyadenylic; polyuridylic acid.
Hovanessian AG; Youn JK; Buffet-Janvresse C; Riviere Y; Michelson M; Lacour J; Lacour F
Cancer; 1985 Jan; 55(2):357-62. PubMed ID: 2578083
[TBL] [Abstract][Full Text] [Related]
10. Polyadenylic.polyuridylic acid in the cotreatment of cancer.
Michelson AM; Lacour F; Lacour J
Proc Soc Exp Biol Med; 1985 May; 179(1):1-8. PubMed ID: 2581264
[TBL] [Abstract][Full Text] [Related]
11. Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor.
Schiller JH; Witt PL; Storer B; Alberti D; Tombes MB; Arzoomanian R; Brown RR; Proctor RA; Voss SD; Spriggs DR
Cancer; 1992 Jan; 69(2):562-71. PubMed ID: 1728387
[TBL] [Abstract][Full Text] [Related]
12. Induced proteins in human peripheral mononuclear cells over a range of clinically tolerable doses of interferon-gamma.
Paulnock DM; Havlin KA; Storer BM; Spear GT; Sielaff KM; Borden EC
J Interferon Res; 1989 Aug; 9(4):457-73. PubMed ID: 2502586
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma.
Fierlbeck G; Ulmer A; Schreiner T; Stroebel W; Schiebel U; Brzoska J
J Interferon Cytokine Res; 1996 Oct; 16(10):777-81. PubMed ID: 8910762
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.
Tilg H; Vogel W; Tratkiewicz J; Aulitzky WE; Herold M; Gruber M; Geissler D; Umlauft F; Judmaier G; Schwulera U
J Hepatol; 1993 Sep; 19(2):259-67. PubMed ID: 8301059
[TBL] [Abstract][Full Text] [Related]
15. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers.
Rothuizen LE; Buclin T; Spertini F; Trinchard I; Munafo A; Buchwalder PA; Ythier A; Biollaz J
J Neuroimmunol; 1999 Sep; 99(1):131-41. PubMed ID: 10496186
[TBL] [Abstract][Full Text] [Related]
16. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
Schiller JH; Storer B; Paulnock DM; Brown RR; Datta SP; Witt PL; Borden EC
J Clin Invest; 1990 Oct; 86(4):1211-21. PubMed ID: 2120284
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer.
Byhardt RW; Vaickus L; Witt PL; Chang AY; McAuliffe T; Wilson JF; Lawton CA; Breitmeyer J; Alger ME; Borden EC
J Interferon Cytokine Res; 1996 Nov; 16(11):891-902. PubMed ID: 8938564
[TBL] [Abstract][Full Text] [Related]
18. Involvement of interleukin-6 and interferon-alpha in the poly(A).Poly(U)-induced 2',5'-oligoadenylate synthetase activity in the mouse monocyte-macrophage cell line, J774A1.
Marin JG; Mencia-Huerta JM; Braquet P; Chabrier PE
J Interferon Cytokine Res; 1996 Mar; 16(3):251-7. PubMed ID: 8697148
[TBL] [Abstract][Full Text] [Related]
19. Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously.
Liberati AM; Garofani P; De Angelis V; Di Clemente F; Horisberger M; Cecchini M; Betti AR; Palmisano L; Astolfi S; Nastari A
J Interferon Res; 1994 Apr; 14(2):61-9. PubMed ID: 8077767
[TBL] [Abstract][Full Text] [Related]
20. A phase I clinical tolerance study of polyadenylic-polyuridylic acid in cancer patients.
Ducret JP; Caillé P; Sancho Garnier H; Amiel JL; Michelson M; Hovanessian AG; Youn JK; Lacour F
J Biol Response Mod; 1985 Apr; 4(2):129-33. PubMed ID: 3998763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
